Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$21.26 +4.5%	$19.43	$14.40 ▼ $47.00	$1.41B	1.33	937,349 shs	2.78 million shs
NTLA Intellia Therapeutics	$8.31 -0.5%	$8.09	$5.90 ▼ $28.18	$860.78M	2.14	2.82 million shs	3.28 million shs
RIOT Riot Platforms	$9.72 -4.8%	$8.23	$6.19 ▼ $15.87	$3.47B	4.53	27.41 million shs	39.13 million shs
VIVO Meridian Bioscience	$33.97	$33.70	$20.35 ▼ $34.38	$1.50B	0.23	973,737 shs	N/A

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	0.00%	-0.42%	+3.96%	+4.47%	-38.68%
NTLA Intellia Therapeutics	0.00%	+2.72%	-2.24%	-13.26%	-66.96%
RIOT Riot Platforms	0.00%	-1.32%	+6.23%	+25.26%	-7.69%
VIVO Meridian Bioscience	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDX Celldex Therapeutics	2.643 of 5 stars	4.5	3.0	0.0	0.0	2.6	0.0	0.0
NTLA Intellia Therapeutics	4.6551 of 5 stars	4.3	1.0	0.0	4.7	3.4	2.5	1.3
RIOT Riot Platforms	2.3672 of 5 stars	3.5	3.0	0.0	0.0	1.0	0.8	1.3
VIVO Meridian Bioscience	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.90	Moderate Buy	$50.90	139.42% Upside
NTLA Intellia Therapeutics	2.67	Moderate Buy	$34.95	320.58% Upside
RIOT Riot Platforms	3.09	Buy	$17.05	75.41% Upside
VIVO Meridian Bioscience	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CLDX, NTLA, RIOT, and VIVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/13/2025	RIOT Riot Platforms	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$13.00 ➝ $14.00
6/3/2025	NTLA Intellia Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $54.00
5/29/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00 ➝ $7.00
5/29/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/20/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/19/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00 ➝ $10.00
5/12/2025	NTLA Intellia Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $45.00
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$7.56M	186.71	N/A	N/A	$9.08 per share	2.34
NTLA Intellia Therapeutics	$45.57M	18.89	N/A	N/A	$11.73 per share	0.71
RIOT Riot Platforms	$458.75M	7.57	$0.82 per share	11.81	$9.14 per share	1.06
VIVO Meridian Bioscience	$333.02M	4.49	$1.78 per share	19.13	$8.41 per share	4.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$141.43M	-$2.70	N/A	N/A	N/A	-1,544.32%	-19.75%	-18.86%	8/6/2025 (Estimated)
NTLA Intellia Therapeutics	-$481.19M	-$5.23	N/A	N/A	N/A	N/A	-49.34%	-40.27%	8/14/2025 (Estimated)
RIOT Riot Platforms	-$49.47M	-$1.32	22.61	N/A	N/A	16.67%	2.15%	2.02%	7/30/2025 (Estimated)
VIVO Meridian Bioscience	$42.46M	$0.97	35.02	∞	N/A	12.70%	16.74%	13.09%	N/A

Latest CLDX, NTLA, RIOT, and VIVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/1/2025	Q1 2025	RIOT Riot Platforms	-$0.25	-$0.90	-$0.65	-$0.90	$159.60 million	$161.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
RIOT Riot Platforms	N/A	N/A	N/A	N/A	N/A
VIVO Meridian Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	24.27	24.27
NTLA Intellia Therapeutics	N/A	6.73	6.73
RIOT Riot Platforms	N/A	5.68	5.68
VIVO Meridian Bioscience	0.07	3.63	2.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
NTLA Intellia Therapeutics	88.77%
RIOT Riot Platforms	40.27%
VIVO Meridian Bioscience	89.72%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	4.40%
NTLA Intellia Therapeutics	3.10%
RIOT Riot Platforms	6.93%
VIVO Meridian Bioscience	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.82 million	Optionable
NTLA Intellia Therapeutics	600	103.58 million	98.59 million	Optionable
RIOT Riot Platforms	340	357.26 million	320.16 million	Optionable
VIVO Meridian Bioscience	702	44.01 million	43.00 million	Optionable

CLDX, NTLA, RIOT, and VIVO Headlines

Recent News About These Companies

Meridian Bioscience Introduces New Enzyme Stabilization Services for Molecular Diagnostics

April 24, 2025 | finance.yahoo.com

Meridian Bioscience Inc (VIVO)

April 10, 2025 | uk.investing.com

India's smartphone mkt grows 6%, Vivo tops

November 13, 2024 | rediff.com

Meridian Bioscience Awarded Bronze Medal by EcoVadis for the Second Consecutive Year in Recognition of Its Continued Dedication to Sustainability

November 7, 2024 | finance.yahoo.com

Meridian Bioscience Gets $500K Top Prize in POC Blood Lead Test Challenge

October 28, 2024 | 360dx.com

Precision BioSciences Launches First Hepatitis B Gene-Editing Trial

October 26, 2024 | precisionmedicineonline.com

Will iQOO 13 launch at same price as iQOO 12? New leak provides major hint

October 25, 2024 | msn.com

Editas strengthens in vivo gene therapy strategy via $238M LNP tech pact with Genevant

October 22, 2024 | fiercebiotech.com

Vivo and Arm collaborate on chip technology innovation, launch joint lab

October 21, 2024 | digitimes.com

vivo and Arm collaborate on chip technology innovation with the unveiling of the vivo Arm Joint Lab

October 18, 2024 | malaysiasun.com

Meridian Growth Legacy MERDX

October 17, 2024 | morningstar.com

Serán Bioscience snags investment from Bain Capital Life Sciences

September 17, 2024 | pehub.com

Vivo T3 Ultra launch on September 12 – check what’s in store for India market

September 6, 2024 | financialexpress.com

Vivo V40 vs Realme GT 6T: How the two mid-range smartphones compare

August 11, 2024 | msn.com

Fast-growing MBX Biosciences raises another $63.5 million in funding

August 6, 2024 | ibj.com

Meridian Bioscience Leads the Way with Innovative Sustainable Solutions for in vitro Diagnostic Manufacturers

July 23, 2024 | finance.yahoo.com

Grant supports Lift Biosciences’ evaluation of IMAN cell therapies in humanized in vivo model systems

May 17, 2024 | bioworld.com

Biomerica, Inc. (BMRA)

May 11, 2024 | finance.yahoo.com

Vivo X100s Pro with new Dimensity 9300 Plus chip could be launching soon

March 24, 2024 | gizmochina.com

Vivo V30 Pro review: Flagship-grade imaging system in a slender form factor

March 13, 2024 | business-standard.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX, NTLA, RIOT, and VIVO Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$21.26 +0.91 (+4.47%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$20.98 -0.28 (-1.32%)

As of 06/13/2025 07:12 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Intellia Therapeutics NASDAQ:NTLA

$8.31 -0.04 (-0.48%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$8.31 0.00 (0.00%)

As of 06/13/2025 07:58 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Riot Platforms NASDAQ:RIOT

$9.72 -0.49 (-4.80%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$9.74 +0.02 (+0.21%)

As of 06/13/2025 07:59 PM Eastern

Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. The company operates through three segments: Bitcoin Mining, Data Center Hosting, and Engineering. It also provides co-location services for institutional-scale bitcoin mining companies; critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners; operation of data centers; and maintenance/management of computing capacity. In addition, the company engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; and electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial, and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.

Meridian Bioscience NASDAQ:VIVO

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time